risks of glp-1 medications The risk in patients taking drugs for obesity or diabetes is higher than with other diabetes drugs, new studies suggest Is GLP-1 the Same as

However, clinicians should recognize that any use of GLP-1 agonists in Crohn's disease patients remains off-label and requires careful consideration of the established evidence base for IBD management

The effect of GLP-1R-based agonists on the hepatic and extra-hepatic complications of MASLD Hepatic diseases The MR analyses indicated that the genetically proxied effects of GLP-1R/GIPR agonists were causally associated with reduced risk of liver cancer (OR: 6.07 10 6 , 95%CI: 8.65 10 8 4.26 10 4 , P = 3.04 10 8 ) while all of the GLP-1R-based agonists did not provide evidence for MASH, chronic hepatitis, liver fibrosis, liver cirrhosis, and hepatic failure (Table 4)

Turns out, some foods are glutathione powerhouses

A Swedish cohort of more than 200,000 individuals with AUD found that those exposed to semaglutide were 36% less likely to be hospitalized for alcohol-related issues, a magnitude that was notably higher than those exposed to the FDA-indicated AUD medications

Glycine also plays a role in creating proteins and offers added benefits such as improved sleep quality and heart and liver protection

In humans gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are the only known insulin stimulating incretin hormones and are released from intestinal cells after food intake 2,3,4,5